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Abstract
Recent association studies in multiple sclerosis (MS) have identified and replicated several single nucleotide polymorphism
(SNP) susceptibility loci including CLEC16A, IL2RA, IL7R, RPL5, CD58, CD40 and chromosome 12q13–14 in addition to the well
established allele HLA-DR15. There is potential that these genetic susceptibility factors could also modulate MS disease
severity, as demonstrated previously for the MS risk allele HLA-DR15. We investigated this hypothesis in a cohort of 1006
well characterised MS patients from South-Eastern Australia. We tested the MS-associated SNPs for association with five
measures of disease severity incorporating disability, age of onset, cognition and brain atrophy. We observed trends
towards association between the RPL5 risk SNP and time between first demyelinating event and relapse, and between the
CD40 risk SNP and symbol digit test score. No associations were significant after correction for multiple testing. We found
no evidence for the hypothesis that these new MS disease risk-associated SNPs influence disease severity.
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Introduction
Many familial and population based studies have demonstrated
the role of genetic factors in susceptibility to multiple sclerosis
(MS). By far the most important and consistently replicated genetic
risk factor associated with MS is the HLA- DRB1*1501-
DQB1*0602 (HLA-DR15) haplotype [1] which carries an odds
ratio of between 2.0 and 3.5 for MS [2].
In the last two years, a series of genome-wide association studies
have identified other SNPs that are associated with multiple sclerosis.
Some of the recent discoveries are polymorphisms in genes for
interleukin 2 receptor alpha (IL2RA), interleukin 7 receptor (IL7R), C-
type lectin, family 16, member A (CLEC16A), ribosomal protein L5
(RPL5)/EV15 locus, CD40, and rs703842 on chromosome 12
[1,3,4,5,6]. Individually, these SNPs contribute a small proportion to
overall MS risk, with allelic odds ratios of between 1.1–1.3 [1,3,4,5,6].
As well as influencing MS risk, the HLA-DR15 haplotype has
been reported to reduce the age of MS onset in MS patients in a
number of large, independent studies from Scandinavia and
Britain [2,7,8,9,10] although this was not replicated in a large US
study [11]. Interestingly, in one of these studies [2], the HLA-
DR15 allele was significantly more frequent in patients with
definite MS than in patients with possible or probable MS (defined
according to the Poser criteria) which may be a proxy for severity.
In another study HLA-DR2 (which includes the HLA-DR15 risk
allele), was associated with increased risk of a more severe course
of disease [12]. In addition HLA-DR15 positivity has been
associated with increased lesion load at MS onset [13]. At the most
benign end of the wide phenotypic MS spectrum, it may be an
entirely subclinical disease, exemplified in twin studies, in which
13% percent of asymptomatic monozygotic twins and 9% of
asymptomatic dizygotic twins of MS index cases exhibited cerebral
MRI lesions typical of MS [14]. It is therefore possible that MS
susceptibility alleles actually represent determinants of severity,
acting at the mildest end of the MS spectrum, by increasing the
likelihood of clinically overt disease and thus, diagnosis. If this
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10003were the case, and if genetic modulation of MS severity were
present across the clinical spectrum of disease, one might also be
able to detect an influence of risk SNPs on MS phenotype,
manifesting as an increased disease severity in MS patients
carrying the risk SNPs.
In order to test this hypothesis, we have chosen to examine the
potential contribution of the susceptibility SNPs in IL2RA, IL7R,
CLEC16A, RPL5, CD40, CD58 and the Chr12 loci to MS severity,
using a well-defined cohort of 1006 patients with relapsing-
remitting and secondary progressive MS from Australia. MS
clinical outcome measures used in this study included age of onset,
time interval from the first demyelinating event (FDE) to first
relapse, and MS Severity Score (MSSS). Cerebral atrophy was
assessed using a validated linear cerebral MRI measure, the
intercaudate ratio (ICR), for 755 patients. In addition, cognitive
testing using the symbol digit modalities test (SDT) was available
for 869 patients.
Materials and Methods
Patients
The ethics committees involved were the Melbourne Health
Human Research and Ethics Committee (HREC) (lead commit-
tee), Eastern Health HREC, Box Hill, Austin and Repatriation
Hospitals HREC, Heidelberg, Barwon Health HREC, Geelong,
St Vincent’s Hospital HREC, Fitzroy, Ballarat Base Hospital
HREC, Ballarat, Gippsland Base Hospital HREC, Sale (all in
Victoria), Albury Base Hospital HREC, Albury, (NSW) and the
Tasmania Health and Medical HREC (Tasmania). The ethics
committees approved the project and signed informed consent was
obtained from all participants.
A total of 1006 patients with relapsing-remitting (RRMS) and
secondary progressive MS (SPMS) were recruited from Victorian
and Tasmania in South-Eastern Australia between 2002 and 2004
[4,15,16].
All of the patients were assessed by six MS specialist
neurologists. Clinical information including the age of onset, sex,
time interval between first demyelinating event and first relapse,
number of relapses and disease course of patients was collected.
Disability in patients was determined using the Kurtzke Expanded
Disability Status Scale (EDSS) The EDSS is a 10-point disease
severity score with half-point increments which itself is derived
from 9 ratings for individual neurological domains, including
visual, brainstem, motor, sensory, cerebellar, bladder/bowel and
cognitive function, and walking distance [17]. The EDSS was used
in combination with disease duration to calculate the MS Severity
Score (MSSS) with reference to the global MSSS table. The MSSS
table essentially ranks individuals from lowest EDSS to highest
EDSS for a given disease duration, and expresses this as a decile
rank between 0 (least affected) and 10 (most severely affected) [18].
Cognitive disability was also assessed in 869 patients using the
symbol digit modalities test (SDT) of the Wechsler Adult
Intelligence Scale-revised [19]. SDT scores were adjusted for
disease duration.
Age of onset was defined as the age at which the patient
experienced their first demyelinating event and the interval
between first demyelinating event and first relapse was determined
from patient recall facilitated by a detailed questionnaire (provided
to participants prior to the clinical assessment) and confirmed by
medical notes (obtained wherever possible from their treating
physician). Based on the country of birth of the participant’s grand
parents, the subjects were predominantly of Northern European
ancestry, the majority were of Anglo Celtic (73%) or Southern
European descent (16%). The remainder were of Western
European (5%), Eastern European (4%), Scandinavian (1%) or
other (1%) descent.
Genotyping
DNA was collected and extracted from blood samples using
either the Nucleon Genomic DNA Extraction Kit (GE Lifescience)
or phenol-chloroform extraction. The majority of SNPs were
genotyped at the Broad Institute for Genotyping and Analysis
(http://www.broad.mit.edu/gen_analysis/genotyping/) with Se-
quenom’s MassARRAY platform (San Diego, CA, USA) using the
iPlex SNP assay design system [4]. However the SNPs rs6074022
and rs703842 were genotyped or imputed in a subset of 898
RRMS and SPMS patients as part of a genome-wide association
study [5], either in the GWAS phase (Illumina 370CNV arrays,
n=581) or in the replication phase (Sequenom MassARRAY
platform, n=317). Presence or absence of the HLA-DR15 allele
was determined from HLA-DRB1 typing performed previously in
954 of the cases using sequence-specific oligonucleotide hybrid-
ization and nucleotide sequencing [6].
MRI assessment
Existing MRI scans were retrieved for measurements of linear
markers of brain atrophy. Scans were available for 755 of the
patients.
The clinical scans were performed at multiple centres and a
variety of protocols were used, but generally the T1-weighted axial
scans were of 5mm thickness with either no gaps (inter-leaved) or
2.5mm gaps. Intercaudate distance (ICD) was described as the
minimum distance between the medial borders of the head of the
caudate nuclei as previously described and validated [20]. The
intercaudate ratio (ICR) was calculated as a fraction of the ICD to
the transverse skull diameter (TSD) where the TSD was defined as
the minimum distance separating the inner borders of the skull at
the level of the most rostral part of the frontal horns. ICD and
TSD were obtained from the same MRI slice, specifically the most
caudal axial T1-weighted slice on which the frontal horns were at
maximal width. ICR was log-transformed to give a more
normally-distributed phenotype, and adjusted for the disease
duration.
Statistical Analysis
Five measurements of disease severity (MSSS, age of onset, time
between the FDE and first relapse, duration-adjusted SDT and
duration-adjusted log(ICR)) were tested for association with SNPs in
CLEC16A (rs6498169), IL2RA (rs2104286), IL7R (rs6897932), CD58
(rs12044852), RPL5 (rs6604026), CD40 (rs6074022) genes and at
Chr12q13–14 (rs703842). Statistical analysis was performed using
Stata 10 statistical software (StataCorp). Testing was performed by
regression of continuous severity variables on the number of minor
alleles carried by patients. All traits were approximately normally
distributed except for MSSS (uniformly distributed by definition). For
nominal genotype-phenotype associations (p,0.05), further analyses
were performed, stratifying by sex and presence or absence of HLA-
DR15. In addition, mean values and 95% confidence intervals were
calculated for each severity variable, stratified by genotype. For
variablesassociated with diseaseduration (ICR and SDT),means and
confidence intervals were standardized to the mean disease duration
(13.4 years) using the Stata ‘lincom’ command. The statistical
methodology used in this paper has been previously published [16].
Results
There were 1006 patients in total, of whom 78% were female.
Patient demographic information is displayed in Table 1.
Genetics of MS Severity
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DR15. Mean values of each of the MS severity variables were
similar in each of the categories of females and males, and DR15-
positive and DR15-negative individuals with the exception of age
of onset, which was lower in DR15-positive patients, as expected
in a cohort of northern European origin [21]. The ranges for each
variable were; MSSS 0.05–9.82, Age of onset 7-65yrs, time
between first demyelinating event (FDE) and first relapse 0–52 yrs,
SDT 0–80, log(ICR) 21.099 to 22.996, means and standard
deviations for these variables are shown in Table 1. Table 2 shows
means and 95% confidence intervals for each of the severity
measures stratified by genotype at each of the tested MS
susceptibility SNPs. Due to the continuous nature of sample
collection, some individuals were not typed for rs6074022 or
rs703842, for which 897 and 898 genotypes were available,
respectively, and for other assays, genotyping results were rejected
in up to 5% of reactions when SNPs were called ambiguously.
The effects of risk SNPS in this cohort of patients was analysed
against five MS severity variables, and the results of this analysis
are expressed as estimated change in disease severity variable for
each additional minor allele (Table 3).
No associations were found between MS-risk-associated SNPs
and MSSS, age of onset, or ICR. We observed a trend towards
association between the RPL5 SNP rs6604026 and the time
between FDE and first relapse (p=0.024), and between the CD40
SNP rs6074022 and the duration of illness adjusted SDT score
(p=0.016). For both of these associations the minor, disease-
associated allele was associated with more severe disease, however
these trends were not significant after applying the Bonferroni
correction for multiple testing, the threshold for which was
p=0.05/35=0.0014.
To account for the possibility that particular subgroups of
patients might exhibit different genotype-phenotype effects, we
stratified the effect of RPL5 (rs6604026) genotype on the time
between FDE and first relapse, and the effect of CD40 (rs6074022)
genotype on the SDT score by either sex or HLA-DR15 status.
In the subgroup analysis, the effect of RPL5 (rs6604026) on the
time between FDE and first relapse was very similar between
groups. There was no significant interaction or trend between
rs6604025 and sex (p=0.915) or between rs6604025 and HLA-
DR15 status (p=0.650) (Table 4). When CD40 (rs6074022) results
were stratified by sex, there was a weak trend towards a stronger
effect in males than females (coefficients 23.1247 and 21.1795
respectively), and a weak trend towards a stronger effect in HLA-
DR15 negative individuals than HLA-DR15 positive individuals
(coefficients 21.8818, and 20.9834 respectively), but these trends
were not significant (interaction p-values 0.475 and 0.224,
respectively) (Table 4).
Discussion
In this study, we investigated whether seven recently identified
MS risk-associated SNPs were acting as modifiers of severity on
any of five markers of MS severity in a large cohort of relapsing-
remitting and secondary progressive MS patients from south-
eastern Australia. We chose to investigate these associations using
an additive, allele-load model of inheritance, rather than recessive
and dominant models, to reduce multiple testing. We found no
evidence that any of the tested SNPs modified the clinical
phenotypes of MSSS, age of onset or the time between FDE and
first relapse. We also did not detect an effect of the risk SNPs on
cerebral atrophy as measured by the ICR, and no evidence of
effects on cognitive function as measured by the SDT. We have
previously reported that none of the seven risk-associated SNPs
tested here are determinants of relapsing versus primary
progressive phenotypes [5]. Similarly, a recent genome-wide
association study of 1000 people with MS [22] investigated SNP
markers associated with age of onset, MSSS, cerebral atrophy and
T2 lesion load, and none of the seven risk SNPs assessed in this
study were reported as showing strong trends of association with
the tested phenotypic variations.
In our study, MS risk-associated SNPs in CD40 and RPL5
showed weak trends towards association with specific disease
severity measures, namely with ICR and time between FDE and
first relapse, respectively. These associations were not significant
after appropriate correction for multiple testing. As these two
SNPs may potentially only be associated with disease severity in
subgroups of patients, the subjects were stratified on two known
risk factors, sex and HLA-DR15 status. There was weak, non-
significant evidence that the CD40 SNP has a stronger effect on
ICD in males and HLA-DR15 negative individuals. The observed
lack of effect of CD40 on phenotype is consistent with a previous
study of disease severity (EDSS), which used an extremes of
severity approach and could not detect an association between
severity and CD40 genotype [23].
This study only examined associations between the identified
risk SNP genotypes and MS disease severity. The currently
identified risk SNPs may be causative, or they may be in linkage
disequilibrium with as yet unidentified SNPs in the same or
neighbouring candidate genes, which could potentially carry
stronger associations with MS. Fine mapping or sequencing of
genetic regions near the currently identified risk SNPs will
probably refine the current MS genetic associations and could
Table 1. Demographic and clinical data for 1006 MS patients with RRMS or SPMS.
Metric Total Females Males HLA-DR15- HLA-DR15+
Patients 1006 781 225 414 540
Age of onset 31.20 (9.84) 31.15 (9.74) 31.36 (10.19) 32.08 (10.18) 30.46 (9.56)
Time between FDE and 1
st relapse
(N=1002)*
5.13 (6.53) 5.01 (6.22) 5.56 (7.51) 5.25 (6.31) 5.03 (6.29)
MSSS 4.12 (2.62) 3.96 (2.54) 4.70 (2.79) 4.10 (2.58) 4.20 (2.63)
Symbol Digit Test (N=850) 41.44 (12.69) 43.09 (12.26) 35.51 (12.49) 41.43 (12.32) 41.21 (13.06)
Log (ICD/TCD) ratio (N=755) 22.08 (0.30) 22.11 (0.30) 21.99 (0.26) 22.08 (0.28) 22.08 (0.31)
All results shown as: Mean (standard deviation).
*FDE=first demyelinating event.
HLA-DR15 status was available for 954 patients.
doi:10.1371/journal.pone.0010003.t001
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disease severity.
In the analyses utilising the full sample (eg MSSS outcomes), our
study had 80% power to detect associations with SNPs that
account for at least 1.6% of a trait’s variance, Due to missing data,
power was reduced in some analyses. For the smallest sub-sample
(MRI outcomes) we had 80% power to detect associations with
SNPs that account for at least 2.1% of variance after correction for
the 35 tests in Table 3 (significance level of p=0.0014). We had
80% power to detect nominally significant associations (p=0.05)
with SNPs that account for at least 0.8% of a trait’s variance (full
sample) or at least 1.0% of variance (individuals with MRIs).
Given that our study did not show significant associations
between individual risk SNPs and MS severity, we would not
expect interactions between multiple SNPs to greatly influence MS
severity. However, although the cohort size of this study is large, it
still does not permit formal testing of interaction hypotheses, as
even interaction tests between any two of the seven risk SNPs
would result in 42 interactions to be tested, and the power of such
a study would be very low.
Interaction tests between treatment exposures and risk SNPs for
association with MS severity are also difficult to conduct because
of power issues. However, at the time of clinical assessment, 71%
of the study cohort was on treatment with one of four disease-
modifying drugs available at the time. If there were a large, SNP-
specific treatment effect, we would expect to detect it in this study
as the particular SNP would, in this case, be a characteristic of the
individuals with reduced MS severity.
Few allelic variations associated with MS severity have been
found, and the only one to be confirmed in multiple studies is the
association between increasing allele load of HLADR15 and lower
age at MS onset [2,7,8,9,10]. The effect of HLA-DR15 on other
markers of disease severity is contentious. While some studies have
shown no effect [24,25], other studies have shown that HLA-DR15
influencesseveral othermarkersofMSdiseaseseverityincludingthe
number of lesions at presentation [13], normalized brain volume,
cognitive function [26] and even the type of early clinical
manifestation of MS [27]. Of the three alleles of the apoE gene,
ApoE4 has been reported to be associated with worse outcome, but
large studies, including our own [16]and a recent meta-analysis [28]
did not confirm any of these effects. Other, as yet unreplicated
disease-modifier SNPs have been reported. For example, a SNP in
IL-1b, which leads to higher expression of the protein, has been
reported to be associated with more benign disease, as assessed by
duration-adjusted EDSS [29]. Two different polymorphisms in the
promoter region of the matrix metalloproteinase 9 (MMP9) gene
areassociatedwithhigherMMP9expressionand,inMScases,were
reported to lower the age-of-onset [30,31] however this effect was
not replicated in another study [32]. Polymorphisms in the
interleukin 4 gene and its receptor (IL4R) have also been shown
to be associated not only with MS susceptibility [33,34,35] but also
with a primary progressive course [36].
More recently, a genome-wide phenotype-genotype study using
gene-ontology techniques in patients with relapsing-remitting MS
[22] reported that the gene function categories ‘‘antigen processing
and presentation’’ and ‘‘CNS development’’ were enriched in MS
susceptibility whereas the categories of ‘‘axon guidance’’ and
‘‘glutamate signalling processes’’ were implicated in phenotypes of
CNS damage, namely, T2 lesion load and brain volume.
The metrics in this study were chosen because they could be
assessed in a large cohort of people with MS, and thus, it is
Table 4. Nominally significant results (p,0.05) stratified by
sex and DR15 genotype.
EV15/RPL5 CD40
rs6604026 rs6074022
Metric Time 1&2 SDT
Stratification Coef p-val Coef p-val
Overall 20.754 0.024 21.529 0.016
female 20.765 0.033 21.1795 0.086
male 20.679 0.412 23.1247 0.025
DR1522 0.844 0.100 21.8818 0.054
DR15+ 20.540 0.219 20.9834 0.263
Interaction with sex 0.086 0.915 0.93613 0.475
Interaction with DR15 0.304 0.650 21.7919 0.224
P-values arise from tests of whether these fitted coefficients differ significantly
from zero. Time 1& 2 is the time between the first demyelinating event and first
relapse. Symbol digit test (SDT) scores have been adjusted for disease duration.
doi:10.1371/journal.pone.0010003.t004
Table 3. Tests of association between SNPs and MS disease severity metrics.
MSSS Age of onset Time 1&2 SDT Log(ICR)
Gene SNP
Minor
Allele Alleles MAF N Coef p-val Coef p-val Coef p-val Coef p-val Coef p-val
CLEC16A rs6498169 G A/G 0.371 983 20.020 0.877 0.207 0.669 20.029 0.928 20.228 0.710 0.010 0.536
IL2RA rs2104286 G A/G 0.232 979 0.022 0.879 0.088 0.874 0.465 0.207 0.031 0.964 20.005 0.775
IL7R rs6897932 T C/T 0.246 955 0.024 0.866 0.515 0.327 20.410 0.239 0.569 0.409 20.001 0.951
CD58 rs12044852 A C/A 0.108 958 20.210 0.845 1.982 0.624 0.704 0.793 3.156 0.545 0.111 0.435
EV15/RPL5 rs6604026 C T/C 0.296 957 20.028 0.838 0.221 0.663 20.754 0.024 20.524 0.422 20.011 0.507
CD40 rs6074022 C T/C 0.293 897 0.215 0.102 20.148 0.765 20.289 0.396 21.529 0.016 20.006 0.716
Chr12q13–14 rs703842 C T/C 0.267 898 0.109 0.428 0.022 0.966 0.160 0.654 20.013 0.985 20.013 0.444
MAF is the minor allele frequency. Fitted coefficients (coef) give the estimated change in disease severity metric for carriage of each additional minor allele. P-values
arise from tests of whether these fitted coefficients differ significantly from zero. Symbol digit test (SDT) and intercaudate ratio (ICR) scores have been adjusted for
disease duration. MSSS is the multiple sclerosis severity score. ICR is the intercaudate distance divided by the transverse skull diameter. Time 1& 2 is the time between
the first demyelinating event and first relapse.
doi:10.1371/journal.pone.0010003.t003
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PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10003possible that different measures could detect changes that could
not be assessed here. SDT, for example, is a good screening tool
for cognitive functional ability in MS, but if the various SNPs are
associated with a regional deficit, or a specific functional change,
then such an effect would not be detected in our study. Likewise,
ICR is a validated measure of overall brain atrophy, but if
potential modulating effects of the MS associated SNPs were
brain-region specific, then the change might not be detected in this
study. Additionally, it has been shown that aspects of MS disease
phenotype are population-specific or stratify on the basis of ethnic
origin. For example, in British and Scandinavian cohorts the
HLA-DR2 allele imparts an earlier age of onset of disease
[2,7,8,9,10], whereas in a cohort from the USA no effect was
observed [11]. Beyond this, the potential interactions between
disease associated SNPs and environmental factors may be
different in cold climates than from tropical ones. As such, our
results are particularly applicable to an MS population of
Caucasian of predominantly British origin, resident in the
temperate mid-latitudes (36u–43uS).
In this population, our study provided no evidence that MS
severity or progression was altered by recently confirmed risk
alleles in MS sufferers.
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